Medicinova Financials
This page shows Medicinova (MNOV) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 20 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Medicinova passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Medicinova generates $0.96 in operating cash flow (-$10.6M OCF vs -$11.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Medicinova's EBITDA was -$12.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 28.1% from the prior year.
Medicinova generated -$10.6M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 42.8% from the prior year.
Medicinova reported -$11.0M in net income in fiscal year 2024. This represents a decrease of 28.9% from the prior year.
Medicinova earned $-0.23 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 35.3% from the prior year.
Medicinova held $40.4M in cash against $0 in long-term debt as of fiscal year 2024.
Medicinova had 49M shares outstanding in fiscal year 2024. This represents an increase of 0.0% from the prior year.
Medicinova invested $6.8M in research and development in fiscal year 2024. This represents an increase of 28.3% from the prior year.
Medicinova invested $895 in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 95.8% from the prior year.
MNOV Income Statement
| Metric | Q3'25 | Q2'25 | Q4'23 | Q3'24 | Q4'22 | Q3'23 | Q4'21 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $123K-8.4% | $135K | N/A | $1.0M | N/A | N/A | N/A | $38K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $1.5M-25.0% | $2.0M | N/A | $700K | N/A | $2.4M | N/A | $2.0M |
| SG&A Expenses | $1.8M+25.7% | $1.4M | N/A | $1.4M | N/A | $1.4M | N/A | $1.6M |
| Operating Income | -$3.4M+6.3% | -$3.6M | N/A | -$1.1M | N/A | -$3.9M | N/A | -$3.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$3.1M+7.0% | -$3.3M | N/A | -$723K | N/A | -$3.7M | N/A | -$3.6M |
| EPS (Diluted) | $-0.06+14.3% | $-0.07 | N/A | $-0.01 | N/A | $-0.07 | N/A | $-0.07 |
MNOV Balance Sheet
| Metric | Q3'25 | Q2'25 | Q4'23 | Q3'24 | Q4'22 | Q3'23 | Q4'21 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $47.6M-4.5% | $49.8M-24.8% | $66.3M-2.7% | $68.1M-8.1% | $74.2M-5.4% | $78.4M-10.3% | $87.4M-4.6% | $91.6M |
| Current Assets | $32.9M-6.3% | $35.1M-31.4% | $51.2M-3.4% | $53.0M-10.2% | $59.0M+11.0% | $53.1M-26.2% | $72.0M-5.5% | $76.2M |
| Cash & Equivalents | $32.6M-5.0% | $34.3M-32.8% | $51.0M-1.0% | $51.5M+178.3% | $18.5M-64.8% | $52.5M-26.5% | $71.4M-4.8% | $75.0M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $0-100.0% | $135K | N/A | $1.0M | N/A | N/A | $0 | N/A |
| Goodwill | $9.6M0.0% | $9.6M0.0% | $9.6M0.0% | $9.6M0.0% | $9.6M0.0% | $9.6M0.0% | $9.6M0.0% | $9.6M |
| Total Liabilities | $3.6M+21.8% | $3.0M-23.8% | $3.9M+12.2% | $3.5M-11.4% | $3.9M-26.0% | $5.3M+41.7% | $3.7M-27.5% | $5.1M |
| Current Liabilities | $3.3M+26.0% | $2.6M-19.2% | $3.3M+17.0% | $2.8M-12.1% | $3.2M-29.6% | $4.5M+59.8% | $2.8M-32.6% | $4.2M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $44.0M-6.2% | $46.9M-24.9% | $62.4M-3.5% | $64.7M-7.9% | $70.2M-3.9% | $73.1M-12.6% | $83.7M-3.2% | $86.5M |
| Retained Earnings | -$435.9M-0.7% | -$432.9M-4.1% | -$415.7M-0.5% | -$413.6M-1.6% | -$407.1M-0.7% | -$404.1M-2.8% | -$393.1M-0.5% | -$391.0M |
MNOV Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q4'23 | Q3'24 | Q4'22 | Q3'23 | Q4'21 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.7M+26.2% | -$2.3M-362.2% | -$499K+63.6% | -$1.4M+65.8% | -$4.0M-47.3% | -$2.7M+25.2% | -$3.6M-20.7% | -$3.0M |
| Capital Expenditures | -$2 | N/A | -$22-100.8% | $3K | N/A | N/A | $0-100.0% | $3K |
| Free Cash Flow | -$1.9M | N/A | -$499K+63.7% | -$1.4M | N/A | N/A | -$3.6M-20.6% | -$3.0M |
| Investing Cash Flow | $1 | N/A | $22+100.8% | -$3K+100.0% | -$30.0M | N/A | $0+100.0% | -$3K |
| Financing Cash Flow | N/A | N/A | N/A | N/A | $0 | $0-100.0% | $39K-84.5% | $250K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MNOV Financial Ratios
| Metric | Q3'25 | Q2'25 | Q4'23 | Q3'24 | Q4'22 | Q3'23 | Q4'21 | Q3'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -2741.7%-61.8pp | -2679.9% | N/A | -114.7% | N/A | N/A | N/A | -9605.2% |
| Net Margin | -2473.6%-35.8pp | -2437.8% | N/A | -72.3% | N/A | N/A | N/A | -9544.5% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -6.4%+0.2pp | -6.6% | N/A | -1.1% | N/A | -4.7% | N/A | -3.9% |
| Current Ratio | 9.86-3.4 | 13.26-2.3 | 15.61-3.3 | 18.92+0.4 | 18.51+6.8 | 11.74-13.7 | 25.42+7.3 | 18.12 |
| Debt-to-Equity | 0.08+0.0 | 0.060.0 | 0.060.0 | 0.050.0 | 0.06-0.0 | 0.07+0.0 | 0.04-0.0 | 0.06 |
| FCF Margin | N/A | N/A | N/A | -137.4% | N/A | N/A | N/A | -8049.5% |
Similar Companies
Frequently Asked Questions
Is Medicinova profitable?
No, Medicinova (MNOV) reported a net income of -$11.0M in fiscal year 2024.
What is Medicinova's earnings per share (EPS)?
Medicinova (MNOV) reported diluted earnings per share of $-0.23 for fiscal year 2024. This represents a -35.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Medicinova's EBITDA?
Medicinova (MNOV) had EBITDA of -$12.7M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Medicinova's free cash flow?
Medicinova (MNOV) generated -$10.6M in free cash flow during fiscal year 2024. This represents a -42.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Medicinova's operating cash flow?
Medicinova (MNOV) generated -$10.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Medicinova's total assets?
Medicinova (MNOV) had $55.9M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Medicinova's capital expenditures?
Medicinova (MNOV) invested $895 in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Medicinova spend on research and development?
Medicinova (MNOV) invested $6.8M in research and development during fiscal year 2024.
How many shares does Medicinova have outstanding?
Medicinova (MNOV) had 49M shares outstanding as of fiscal year 2024.
What is Medicinova's current ratio?
Medicinova (MNOV) had a current ratio of 13.88 as of fiscal year 2024, which is generally considered healthy.
What is Medicinova's debt-to-equity ratio?
Medicinova (MNOV) had a debt-to-equity ratio of 0.06 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Medicinova's return on assets (ROA)?
Medicinova (MNOV) had a return on assets of -19.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Medicinova's cash runway?
Based on fiscal year 2024 data, Medicinova (MNOV) had $40.4M in cash against an annual operating cash burn of $10.6M. This gives an estimated cash runway of approximately 46 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Medicinova's Piotroski F-Score?
Medicinova (MNOV) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Medicinova's earnings high quality?
Medicinova (MNOV) has an earnings quality ratio of 0.96x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.